from KW website , news p2 , third from bottom up “….China Grand Pharma’s strategy is to become the foremost nuclear medicine company in the Greater China Region.
To this end, it has been building up a portfolio of products and technologies and the Telix deal strengthens China Grand Pharma’s position in the nuclear medicine sector in the region.
Two years ago, China Grand Pharma teamed with the PE firm, CDH Investments, to acquire Sirtex for $1.9 billion, beating US company Varian Medical Systems’ bid of $1.6 billion.
David Williams, Managing Director of Kidder Williams, said “China Grand Pharma is opening new markets to some of Australia’s best technology and supporting Australian research with capital and clinical evidence”.China Grand Pharma was advised by Kidder Williams …”
who is advising Oncosil? Yep, you know the answer.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)